JSPRW Jasper Therapeutics, Inc. - Warrant
0.0002USD-84.62%Mkt Cap: —P/E: —14d ago
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-c…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M USD
Revenue/Share—
Last Price0.0002 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-3.84
EPS (Forward)—
52W Range
0.00010% of range0.0204
52W High0.0204 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.30
Current Ratio—
Quick Ratio—
Book Value/Sh0.05 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float—
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)76.20K
Avg Vol (10d)—
Technical Indicators
RSI (14)12.7
MACD-0.0038
MACD Signal-0.0032
MACD Hist.-0.0006
BB Upper0.0166 USD
BB Middle0.0083 USD
BB Lower0.0000 USD
BB Width198.87%
ATR (14)0.0028 USD
Vol Ratio (20d)12.60x